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Abstract
Background: There have been few reports regarding long time survival after lung cancer surgery.
The influence of age and pulmonary function on long time survival is still not fully discovered. Some
reports suggest that hospitals with a high surgical volume have better results. The aim of this study
was to evaluate lung cancer surgery performed in a county hospital in terms of 30 days mortality,
complications and predictors of long time survival.
Methods: All patients operated with non-small cell lung cancer in the period 1993–2006 were
reviewed, and 148 patients were included in the study. 30 days mortality and complications were
analyzed by univariate analysis. Kaplan Meier plots were performed to display some of the
univariate variables. Cox regression analysis was performed to find Hazard Ratios (HR) that
predicted long time survival in univariate and multivariate analysis.
Results: The overall 30 days mortality rate was 2.7%, whereas 36.3% had one or more
complications after surgery. The median survival time was 3.4 years. In multivariate Cox regression
analysis advanced preoperative stage predicted reduced long time survival with HR (95%CI) 1.63
(0.92, 2.89) and 4.16 (1.92, 9.05) for patients in stage IB and II-IV respectively, when compared to
patients in stage IA. Age ≥ 70 years and FEV1<80% predicted reduced long time survival with HR
(95%CI) 2.23 (1.41, 3.54) and 1.93 (1.14, 3.28) respectively, compared to age<70 years and FEV1 ≥
80%.
Conclusion: Thirty days mortality and complication rate showed that lung cancer surgery can be
performed safely in a county hospital with experienced thoracic surgeons. Early preoperative stage,
age below 70 years and normal pulmonary function predicted long time survival.
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The epidemiology of lung cancer has changed dramati-
cally within the last 40 years. The incidence has increased,
especially among women, and there are more adenocarci-
nomas. The number of surgical candidates in stage I and
II disease have increased both for patients below and
above 70 years [1-3]. There is an ongoing debate regarding
centralisation of lung cancer surgery. Generally, hospitals
with low volumes of lung cancer surgery have lower five
years survival and more complications than teaching hos-
pitals and hospitals with high volumes [4]. Predictors of
higher survival rate or lower complication rate have been
female gender [5-10], lower age [5,6,8,9,11,12], early pre-
operative stage [5,13], lobectomy [5,9,12-15], adenocarci-
noma [8,13,16], no previous coronary heart disease [17-
19], and normal pulmonary function tests
[6,9,11,17,20,21]. Some of these predictors have been
analysed only in univariate tests. There are as far as we
know no previous reports from county hospitals where
lung cancer surgery is performed with staff from larger
teaching hospitals.
Aalesund Hospital in Norway is a county hospital with a
catchment area of approximately 100 000 inhabitants.
The aim of this study was to evaluate lung cancer surgery
performed in a county hospital in terms of 30 days mor-
tality, complications and long time survival, and to evalu-
ate predictors of long time survival.
Methods
A total of 149 operations in 148 patients at Aalesund Hos-
pital from 1993 to 2006 with non-small cell lung cancer
(NCLC) were retrospectively reviewed. One patient had
two operations for different lung cancers and only the last
operation was included in further analysis. The medical
records of two patients were not found and these were
excluded from the analysis of complications. The medical
records of all patients were followed to 15.09.2007. Mor-
tality data were available for all patients, but details about
relapse were missing for four patients. All complications
that appeared within 60 days after surgery were registered.
Pulmonary embolism and deep venous thrombosis were
included when they appeared within 90 days.
After the locally based specialist in thoracic surgery left in
1997, lung cancer surgery was taken over by three special-
ists from teaching hospitals in Tromsö and Trondheim.
Adjuvant cytostatic treatment was introduced in Novem-
ber 2004. Only six patients received adjuvant chemother-
apy, 10 patients had adjuvant irradiation therapy. Some
advanced stage cases or high risk patients were initially
referred to the regional hospital for treatment during the
study period, but this was a minority. Pneumectomy was
performed when there was a large central tumor or tumor
invasion of a main bronchus, and the patients had a good
pulmonary function with expected postoperative FEV1
above 1 litre.
The statistical analysis was performed in SPSS using Chi
square tests and Hazard ratio from Cox regression for uni-
variate analysis, and Hazard ratio from Cox regression for
multivariate analysis of survival. Variables described as
significant in previous studies were included in univariate
analyses. All variables in the univariate analyses were
included in the multivariate analysis. Kaplan Meier plots
were performed to estimate median survival time and to
visualize some of the univariate variables.
The Regional Medical Ethics Committee and the Norwe-
gian Social Science Data Service approved the study.
Results
The baseline characteristics of the patients are displayed in
table 1. A malignant diagnosis was obtained for 111
(75%) of the patients before surgery. In 43 cases (29.1%)
the diagnosis was obtained after inconclusive bronchos-
copy by a percutaneous approach. The median time from
bronchoscopy to diagnosis was five days (n = 111, range
1–71 days) and the median time from diagnosis to sur-
gery was 17 days (n = 111, range 0–127). Adenocarci-
noma was the most prevalent histology. The mean age
was 67.3 years (95% CI: 47.0, 87.6). Of the 16 patients
operated with preoperative stage II-IV, distribution was
stage IIA: 2, IIB: 3, IIIA: 6, IIIB: 3 and IV: 2. The patients in
stage IIIB had more than one lesion in the affected lobe.
In stage IV one patient had intrapulmonal metastasis and
one patient had cerebral metastasis. The postoperative
pathological stage was I, II, III, and IV for 89, 38, 15, and
six patients respectively.
The overall complication rate was 36.3%. Pneumonia
(16.4%) and respiratory failure (6.8%) were the most
common complications (Table 2). Table 3 describes the
univariate analyses of complications, 30 day survival and
1 year survival. The overall 30 day mortality rate was 2.7%
(four patients) and one year mortality rate was 18.9%. Age
above 70 years predicted a higher rate of complications (p
< 0.002), higher 30 days mortality (p = 0.02) and higher
one year mortality (p < 0.001). Pneumonectomy and cor-
onary heart disease were predictors of higher 30 day mor-
tality in univariate analysis; and actually no early
mortality was seen after lung resections less than pneu-
monectomy. Causes of early death were respiratory failure
(n = 3) and multiorgan failure (n = 1). Six patients were
re-operated because of complications. Of the 144 patients
eligible for follow-up, 47.9% had relapse of lung cancer.
Median time to relapse was 44.9 months. The relapse rate
was 69.7% in the group with FEV1<80% compared to
30.3% in the group with FEV1 ≥ 80% (n = 138, p = 0.01).Page 2 of 8
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Five years overall survival rate was 41.6% (Fig 1). Figure 2,
3, 4 shows Kaplan Meier plots for long time survival
according to age, preoperative stage, and pulmonary func-
tion. Cox regression analysis showed a significant relation
between long time survival and age, type of operation,
preoperative stage and pulmonary function in univariate
analysis. There was no significant relation between long
time survival and gender or previous coronary heart dis-
ease. Age, preoperative stage and pulmonary function
remained significant in the multivariat analysis (Table 4).
Discussion
The 30 days mortality rate of 2.7% in this study was com-
parable or lower than previously reported from high vol-
Table 2: Hospital morbidity (n = 146)
N %
Any complications 53 36.3
Wound infection 5 3.4
Postoperative bleeding 3 2.1
Pneumonia 24 16.4
Sepsis 1 0.7
Bronchopleural fistula 2 1.4
Empyema 1 0.7
Drainage of fluid or air 5 3.4
Deep venous thrombosis 1 0.7
Pulmonary embolism 3 2.1
Respiratory failure 10 6.8
Myocardial infarction 5 3.4
Heart failure 3 2.1
Atrial fibrillation 9 6.2
Renal failure (creatinine>140) 2 1.4
Multi organ failure 1 0.7
Cerebral infarction 2 1.4
Other complications 4 2.7
Data are presented as number of positive samples/all samples (%). 
Two patients were excluded because of insufficient information.
Table 1: Baseline characteristics of 148 patients operated for 
lung cancer
n %
Sex
Female 48 32.4
Male 100 67.6
Age
< 70 years 86 58.1
≥ 70 years 62 41.9
Preoperative stage
IA (T1 N0 M0) 64 43.2
IB (T2 N0 M0) 68 45.9
II-IV 16 10.8
Operation type
Lobectomy 97 65.5
Pneumonectomy 30 20.3
Bilobectomy 16 10.8
Wedge 5 3.4
Histology
Adenocarcinoma 73 49.3
Squamous cell carcinoma 53 35.8
Large cell carcinoma 14 9.5
Other non-small cell carcinoma 8 5.4
Coronary heart disease
No previous coronary disease 107 72.3
Previous coronary disease 41 27.7
Pulmonary function
FEV1 ≥ 80% 62 41.9
FEV1<80% 77 52.0
Indeterminate 9 6.1
Data are presented as number of positive samples/all samples (%).Page 3 of 8
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Table 3: Univariate analysis of 30 days mortality, complications and 1 year mortality.
n 30 days mortality p Complications* p 1 year mortality p
Sex 0.16 0.37 0.07
Female 48 0% 31.3% 10.4%
Male 100 4% 38.8% 23.0%
Age 0.02 0.002 <0.001
< 70 years 86 0% 25.9% 9.3%
≥ 70 years 62 6.5% 50.8% 32.3%
Preoperative stage 0.09 0.18 0.04
IA (T1 N0 M0) 64 0% 31.3% 10.9%
IB (T2 N0 M0) 68 5.9% 36.4% 22.1%
II-IV 16 0% 56.3% 37.5%
Operation type 0.001 0.29 0.11
Lobectomy 97 0% 31.3% 15.5%
Pneumonectomy 30 13.3% 46.7% 33.3%
Bilobectomy 16 0% 40% 18.8%
Wedge 5 0% 60% 0%
Histology 0.57 0.35 0.21
Adenocarcinoma 73 1.4% 33.3% 13.7%
Squamous cell carcinoma 53 3.8% 42.3% 22.6%
Large cell carcinoma 14 7.1% 42.9% 35.7%
Other non-small cell carcinoma 8 0% 12.5% 12.5%
Coronary heart disease 0.03 0.84 0.91
No previous coronary disease 107 0.9% 36.8% 18.7%
Previous coronary disease 41 7.3% 35.0% 19.5%
Pulmonary function 0.22 0.40 0.86
FEV1 ≥ 80% 62 4.8% 33.9% 19.4%
FEV1<80% 77 1.3% 40.8% 18.2%
Statistical analysis: χ2.
*Two patients excluded because of insufficient information.
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overall survival rate of 41.6% is comparable to previous
reports from larger centres [5,8,13]. The higher 30 days
mortality and morbidity rate among elderly patients and
following pneumonectomy have previously been
described [7,11,12], but the relation have not been signif-
icant in all studies [19]. The early complication rate is
prone to information bias in a retrospective study, but our
report of 36.3% with ≥ 1 complication was within the
same range as in previous reports [4,7,12,13].
Age above 70 years and a more advanced preoperative
stage were predictors of reduced long time survival in this
study as well as in some previous studies [5,13,22]. Thus,
these variables should routinely be included in future
multivariate analyses. The increased survival of female
gender has previously been described [5,10], but like
comparable studies, we could not find any significant
effect of gender [13].
FEV1 < 80% predicted reduced long time survival by mul-
tivariate analysis. The predictors of long time survival
Postoperative survival curve (Kaplan-Meier plot) for all patientsFigure 1
Postoperative survival curve (Kaplan-Meier plot) for all 
patients.
Kaplan-Meier plot for overall survival stratified by ageFigure 2
Kaplan-Meier plot for overall survival stratified by age.
Kaplan-Meier plot for overall survival stratified by preopera-tive stageFigure 3
Kaplan-Meier plot for overall survival stratified by preopera-
tive stage.
Kaplan-Meier plot for overall survival stratified by preopera-tive pulmonary functionFigure 4
Kaplan-Meier plot for overall survival stratified by preopera-
tive pulmonary function.Page 5 of 8
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Table 4: Hazard ratio (HR) for survival
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Sex 0.945
Female 1 1
Male 1,28 0.82, 2.0 0.28 1.02 0.59, 1.75
Age 0.001
< 70 years 1 1
≥ 70 years 2.04 1.35, 3.09 0.001 2.23 1.41, 3.54
Preoperative stage 0.003
IA (T1 N0 M0) 1 1
IB (T2 N0 M0) 2.00 1.27, 3.17 0.003 1.63 0.92, 2.89
II-IV 4.59 2.34, 9.02 <0.001 4.16 1.92, 9.05
Operation type
Lobectomy 1 1 0.57
Pneumectomy 2.14 1.34, 3.43 0.002 1.37 0.78, 2.43
Bilobectomy 0.94 0.48, 1.85 0.85 0.84 0.40, 1.76
Wedge 0.70 0.17, 2.88 0.62 0.70 0.16, 3.15
Histology 0.32
Adenocarcinoma 1 1
Squamous cell carcinoma 1.51 0.96, 2.37 0.08 0.86 0.48, 1.54
Large cell carcinoma 2.60 1.36, 4.98 0.004 1.79 0.80, 3.99
Other non-small cell carcinoma 0.63 0.19, 2.04 0.44 0.80 0.24, 2.67
Coronary heart disease 0.73
No previous coronary disease 1 1
Previous coronary disease 1.27 0.81, 1.99 0.31 0.91 0.54, 1.54
Pulmonary function 0.013
FEV1 ≥ 80% 1 1
FEV1<80% 2.30 1.45, 3.65 <0.001 1.93 1.14, 3.28
HR = Hazard Ratio. Statistical analysis: Cox Regression analysis method = enter.
p value: univariate: Wald, multivariate: Likelihood ratio.
BMC Pulmonary Medicine 2008, 8:22 http://www.biomedcentral.com/1471-2466/8/22have been described in different studies. FEV1 can be
treated linearly, with cut off points, or in terms of FEV1/
FVC ratio. One previous study applied FEV1<70% of pre-
dicted and found only a small influence on long time sur-
vival [13]. The present study found a marked difference
between patients with FEV1 ≥ 80% versus FEV1<80% of
predicted value. The cause of death was not registered in
all patients, but the relapse rate in patients with FEV1
<80% was higher than in the group with FEV1 ≥ 80%. We
did not have sufficient information about smoking to
adjust for pack-years. In patients registered for their smok-
ing habits, the consumption of tobacco was similar in the
two groups. The explanation for a higher mortality rate in
the group with FEV1<80% is not known and should be
further investigated. A hypothesis may be that it is more
likely to develop minor pre-cancerous lesions when
tobacco smoke has caused lung injury in patients suffering
from chronic obstructive lung disease.
Strengths of this study were the long observation time and
that all operated patients were included. Thus, the study
reflected the complete patient group and the hard end
points were easily assessed, except for the missing early
postoperative data in two patients. A major limitation is
the retrospective design of the study. Although all oper-
ated patients were included, there may have been selec-
tion bias as the surgeons selected their cases. Referral of
some advanced and high risk cases to the regional hospi-
tal may also have contributed to a better long time sur-
vival in this patient group. The main variables well known
to influence on survival were included, but the relatively
low number of patients in this study made it impossible
to adjust for too many factors in the multivariate analysis.
Conclusion
This study has shown that lung cancer surgery performed
in a county hospital with surgeons from teaching hospi-
tals can be performed with good results. The 30 days mor-
tality rate was low and the complication rate was in the
range of previous studies. Predictors of reduced long time
survival were age over 70 years, advanced preoperative
stage and FEV1<80%. The effect of pulmonary function on
long time survival should be investigated in a larger study,
the quality of surgery should be registered prospectively.
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